IDO1-IN-19
IDO1-IN-19 (Compound 17) is an orally active IDO1 inhibitor with an IC50 of CYP2C9 of 8.64 μM. IDO1-IN-19 also acts funciton on cardiac channels, with IC50s of 12 μM (IKr), 40 μM (INa), 8.3 μM (ICa), respectively. IDO1-IN-19 has the potential to study cancer diseases[1].
Product Specifications
CAS Number
[2328099-11-0]
UNSPSC
12352005
Target
Calcium Channel; Cytochrome P450; Indoleamine 2,3-Dioxygenase (IDO) ; Potassium Channel; Sodium Channel
Type
Reference compound
Related Pathways
Membrane Transporter/Ion Channel; Metabolic Enzyme/Protease; Neuronal Signaling
Applications
Cancer-programmed cell death
Field of Research
Cancer; Cardiovascular Disease
Assay Protocol
https://www.medchemexpress.com/ido1-in-19.html
Purity
98.82
Solubility
DMSO : 100 mg/mL (ultrasonic)
Smiles
OC(C)(C)C1=CC(C(F)(F)F)=NC=C1C2=CC=C(C3(COC3)C(NC4=CC=C(F)C=C4)=O)C=C2
Molecular Formula
C25H22F4N2O3
Molecular Weight
474.45
References & Citations
[1]Derun Li, et al. Oxetane Promise Delivered: Discovery of Long-Acting IDO1 Inhibitors Suitable for Q3W Oral or Parenteral Dosing.
Shipping Conditions
Room Temperature
Storage Conditions
-20°C, 3 years; 4°C, 2 years (Powder)
Scientific Category
Reference compound1
Clinical Information
No Development Reported
Isoform
Calcium Channel; CYP2; IDO1; Inwardly rectifying potassium channel
Available Sizes
Explore Other Products
Discover premium biology products from our extensive collection of 20M+ items
G-Protein Coupled Receptor 15 (GPCR15, GPR15, BOB, MGC126828, MGC126830) discontinued
